MNG489
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.411
- G2M_CHECKPOINT+0.328
- MYC_TARGETS_V2+0.316
- E2F_TARGETS+0.312
- BILE_ACID_METABOLISM+0.223
- PEROXISOME+0.211
- ANDROGEN_RESPONSE+0.205
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.189
- CHOLESTEROL_HOMEOSTASIS+0.188
- FATTY_ACID_METABOLISM+0.163
Top 10 suppressed
- ANGIOGENESIS-0.460
- HEDGEHOG_SIGNALING-0.450
- APICAL_SURFACE-0.449
- ALLOGRAFT_REJECTION-0.412
- IL6_JAK_STAT3_SIGNALING-0.391
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.389
- MYOGENESIS-0.347
- INFLAMMATORY_RESPONSE-0.335
- COMPLEMENT-0.287
- KRAS_SIGNALING_UP-0.279
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A8-A06Q-01A-11R-A034-07 | — | C | 0.877 |
| 2 | TCGA-P3-A5QF-01A-11R-A28V-07 | — | — | 0.866 |
| 3 | 1ac3f1b2-5b83-470c-b1d3-d35d813f3e65 | — | — | 0.862 |
| 4 | TCGA-BA-A6DL-01A-21R-A30B-07 | — | — | 0.852 |
| 5 | SRR12475110 | — | — | 0.846 |
| 6 | TCGA-E2-A14W-01A-11R-A12D-07 | — | B | 0.840 |
| 7 | TCGA-B6-A0X5-01A-21R-A109-07 | — | B | 0.838 |
| 8 | bbeadeec-bb57-4762-8828-3bd1696748fb | — | — | 0.837 |
| 9 | a8ce7460-8ccd-4638-a854-55c4068af6ec | — | — | 0.837 |
| 10 | TCGA-BH-A1FJ-01A-11R-A13Q-07 | — | B | 0.835 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.411 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.328 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.316 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.312 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.223 | Inavolisib | — uncovered |
| PEROXISOME | 0.211 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.205 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.189 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.188 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.163 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.158 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.155 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.129 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.088 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.066 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.039 | Temsirolimus | — uncovered |
| GLYCOLYSIS | 0.034 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.018 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.014 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.007 | Idelalisib | — uncovered |